Member Info for EmeraldCarrots

Not out of the woods yet, but no more dilution imminent.

If we could have some good news then the Company would be in a better position for funding.

Still further looking at the 42%. Will he bid? I ain't selling for less than 2p a share.

..

Ask now 0.55p, up about 50%

1p today?

Shorters just got incinerated.

The crooks have screwed up. RNS - the vote is NO. No share dilution. Ask now 0.45p Up what............ 40%?

Result of vote not known yet, so bunch of crooks on here. They will be banned.

The vote has not been done! Crooks posting here.

Result of AGM vote won't be known until later today. Crooks posting on here.

Almost no policing here. Result of vote won't be until later.

That can't be right as no RNS yet.

For control?

To buy the Company he only needs another 35.1% which he could bid say 1.5p a share for. Only 35.1% would have to accept. I changed my mind again. I think he will buy GDR............ if he feels he really needs to. I think that is a fall back position.

All IMHO.

Solid tumor and the circulating tumour cells (CTC's) if there are any. The problem is the so called "gold standard" solid tissue analysis is "what we have always done" (as there was no other way!). Cancer research is still in the dark ages with the "that's what we have always done" attitude. Only testing the solid tumour tissue for biomarkers (assuming you can) is completely out of date. CTC's need to be tested too.

All IMHO.

Analysis of ctcs?

A.I.

In most cases, the analysis of solid tumors is less representative than that of circulating tumor cells (CTCs) because a single solid tumor biopsy is limited by spatial and temporal heterogeneity. A tissue biopsy provides a static snapshot of only a single, localized area of the tumor at one point in time. In contrast, analyzing CTCs through a liquid biopsy offers a real-time, comprehensive, and dynamic look at the overall genetic and phenotypic landscape of both the primary tumor and all metastatic sites.

Here is a comparison of how representative each method is for different aspects of cancer analysis.

Spatial heterogeneity

Tumors are not uniform; they contain different subpopulations (subclones) of cells with varying genetic and molecular characteristics in different areas.

Analysis

Representativeness

Solid tumor analysis Low. A single biopsy is highly susceptible to sampling bias, as it can easily miss aggressive or resistant subclones located in other parts of the tumor. Studies have shown that single biopsies can misclassify the overall mutational status of a tumor.

CTC analysis High. CTCs are shed into the bloodstream from various regions of the primary and metastatic tumors. Analyzing CTCs provides an "average signal" of the tumor's overall burden throughout the body, capturing a broader range of the tumor's genetic diversity.

To catch the circulating tumor cells (CTC's) from a standard blood sample for analysis.

1. Parsortix catches live, intact, uncontaminated CTC's so can undergo DNA analysis the same way Myriad already analyse solid tumour samples.

2. The CTC's can undergo any tests that are available now and it the future as they are live, intact and uncontaminated.

3. Myriad using Parsortix would be excellent marketing material for Myriad Genetics. "Our biomarker analysis now includes both solid tumor and circulating tumor DNA for the complete picture".

4. Parsortix is faster and does not involve as many chemicals as competing ways to catch CTC's.

I can't see Myriad not using parsortix.

All IMHO.

But they are much older than any samples you might find in circulating tumour cells (CTC's), are they not, and cancer changes over time. Myriad Genetics already offer the complete analysis of solid tumor samples, including DNA analysis, that is part of what they do. Now we have been told by Angle they are looking to possibly add the DNA analysis of CTC's to their offerings. Makes perfect sense from where I'm sitting.

==============

Also it would be excellent marketing material for Myriad Genetics.

"Our biomarker analysis now includes both solid tumor and circulating tumor DNA for the complete picture".

==============

Another advantage of Myriad using Parsortix to catch the CTC's would be they are live, intact and uncontaminated so they would be available for any other tests that may crop up in the future, like protein expressions etc....

Have ordered a complete roll out in Scotland then gawd help us. Early days so I expect big progress driven by the Scottish NHS news.

All IMHO.